Hugel, Inc. (KOSDAQ:145020)
South Korea · Delayed Price · Currency is KRW 225,500
-5,500 (-2.38%)
Nov 19, 2025, 3:30 PM KST
Hugel Revenue
Hugel had revenue of 105.90B KRW in the quarter ending September 30, 2025, with 0.75% growth. This brings the company's revenue in the last twelve months to 404.19B, up 11.11% year-over-year. In the year 2024, Hugel had annual revenue of 373.05B with 16.69% growth.
Revenue (ttm)
404.19B
Revenue Growth
+11.11%
P/S Ratio
6.02
Revenue / Employee
686.23M
Employees
589
Market Cap
2.43T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 373.05B | 53.35B | 16.69% |
| Dec 31, 2023 | 319.70B | 38.02B | 13.50% |
| Dec 31, 2022 | 281.68B | 49.82B | 21.49% |
| Dec 31, 2021 | 231.86B | 20.82B | 9.87% |
| Dec 31, 2020 | 211.04B | 6.47B | 3.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |